Nuveen
ESPR

Nuveen’s Esperion Therapeutics ESPR Stock Holding History

Nuveen’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.82M Sell
574,806
-3,038,903
-84% -$8.5M ﹤0.01% 2624
2026
Q1 		$9.9M Buy
3,613,709
+1,596
+0% +$5.05K ﹤0.01% 1562
2025
Q4 		$13.4M Sell
3,612,113
-98,956
-3% -$320K ﹤0.01% 1383
2025
Q3 		$9.83M Buy
3,711,069
+3,288,456
+778% +$6.36M ﹤0.01% 1567
2025
Q2 		$416K Sell
422,613
-2,665,087
-86% -$2.67M ﹤0.01% 2941
2025
Q1 		$4.45M Sell
3,087,700
-31,553
-1% -$58.1K ﹤0.01% 1982
2024
Q4 		$6.86M Buy
3,119,253
+1,020,243
+49% +$2.38M ﹤0.01% 1819
2024
Q3 		$3.46M Sell
2,099,010
-173,618
-8% -$351K ﹤0.01% 2162
2024
Q2 		$5.05M Buy
+2,272,628
New +$5.35M ﹤0.01% 1950
2023
Q2 		– Sell
-792,772
Closed -$1.26M – 3232
2023
Q1 		$1.26M Sell
792,772
-226,424
-22% -$1.17M ﹤0.01% 2517
2022
Q4 		$6.35M Buy
1,019,196
+717,837
+238% +$5.13M ﹤0.01% 1781
2022
Q3 		$2.02M Buy
301,359
+106,392
+55% +$731K ﹤0.01% 2400
2022
Q2 		$1.24M Sell
194,967
-145,932
-43% -$827K ﹤0.01% 2692
2022
Q1 		$1.89M Buy
340,899
+261,772
+331% +$1.12M ﹤0.01% 2531
2021
Q4 		$395K Sell
79,127
-18,987
-19% -$152K ﹤0.01% 3126
2021
Q3 		$1.23M Sell
98,114
-67,884
-41% -$988K ﹤0.01% 2910
2021
Q2 		$3.51M Sell
165,998
-48,136
-22% -$1.16M ﹤0.01% 2425
2021
Q1 		$6.01M Buy
214,134
+95,919
+81% +$2.83M ﹤0.01% 2086
2020
Q4 		$3.07M Sell
118,215
-8,144
-6% -$244K ﹤0.01% 2293
2020
Q3 		$4.7M Sell
126,359
-38,767
-23% -$1.54M ﹤0.01% 1951
2020
Q2 		$8.47M Sell
165,126
-19,221
-10% -$804K ﹤0.01% 1595
2020
Q1 		$5.81M Buy
184,347
+20,371
+12% +$1.08M ﹤0.01% 1621
2019
Q4 		$9.78M Sell
163,976
-125,700
-43% -$5.65M ﹤0.01% 1601
2019
Q3 		$10.6M Sell
289,676
-95,068
-25% -$3.77M ﹤0.01% 1534
2019
Q2 		$17.9M Buy
+384,744
New +$18.1M 0.01% 1222

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Nuveen's ESPR Position: Q2 2026 in Review

Nuveen reduced its Esperion Therapeutics (ESPR) stake by 84% in Q2 2026, selling an estimated $8.5M and leaving 574,806 shares worth $1.82M. The position accounts for ﹤0.01% of the portfolio, ranked #2624.

Nuveen first reported a position in ESPR in Q2 2019 and has held it in 25 quarters since. The position peaked at $17.9M in Q2 2019. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Nuveen held 574,806 shares of Esperion Therapeutics worth $1.82M as of Q2 2026.
  • Nuveen sold 3,038,903 Esperion Therapeutics shares in Q2 2026, an estimated $8.5M.
  • Esperion Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2624 holding.
  • Nuveen first reported a position in Esperion Therapeutics in Q2 2019 and has held it in 25 quarters since.
  • Nuveen's Esperion Therapeutics position peaked at $17.9M in Q2 2019.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.